Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL495596 | 0.89 | TRPV1 (0.40) | TRPV1SCN8ASCN10ARXFP1 | |
| SCHEMBL495861 | 0.73 | TRPV1 (0.43) | TRPV1SCN8ASCN10ARXFP1 | |
| SCHEMBL10129659 | 0.72 | TP53 (0.47) | TRPV1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL496591 | 0.71 | TRPV1 (0.41) | TRPV1SCN8ASCN10ARXFP1 | |
| SCHEMBL10129656 | 0.71 | TP53 (0.44) | TRPV1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL496063 | 0.71 | TRPV1 (0.52) | TRPV1RXFP1 | |
| SCHEMBL495648 | 0.71 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL495351 | 0.71 | ATAD2 (0.48) | BRD4 | |
| SCHEMBL496188 | 0.71 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL496600 | 0.70 | SCN10A (0.43) | TRPV1SCN8ASCN10ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | TRPV1 1/4885MEN1 3066/4885KMT2A 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.